Oramed grants CEO Nadav Kidron 629K conditional shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Oramed Pharmaceuticals granted President and CEO Nadav Kidron two direct restricted stock awards on November 12, 2026. One covers 629,000 shares and vests only if the company’s return on equity for fiscal 2026 exceeds 18%. If that condition is met, half vests when the audited fiscal 2026 financial statements are published and half six months later, subject to continued service; otherwise, all shares are forfeited.
The second award covers 688,000 shares for annual awards for fiscal years 2027 and 2028. It vests in two groups of 344,000 shares, each in 12 substantially equal quarterly installments beginning January 1, 2027, and January 1, 2028, respectively, subject to continued service. No annual award will be granted to Kidron for fiscal 2028.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 629,000 | -- | -- |
| Grant/Award | Common Stock F2 | 688,000 | -- | -- |
Footnotes (2)
- F1. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 629,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan. The shares vest only if the issuer's return on equity for fiscal year 2026 exceeds 18%, in which case 50% vest on the date the issuer's audited fiscal year 2026 financial statements are published and 50% vest six months thereafter, subject to the reporting person's continued service. If the condition is not met, all of the shares will be forfeited.
- F2. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 688,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual awards for fiscal years 2027 and 2028. Of these shares, 344,000 vest in twelve substantially equal quarterly installments beginning January 1, 2027, and 344,000 vest in twelve substantially equal quarterly installments beginning January 1, 2028, in each case subject to the reporting person's continued service. No annual award will be granted to the reporting person for fiscal year 2028.
Key Figures
Key Terms
restricted stock award technical
return on equity financial
Amended and Restated 2019 Stock Incentive Plan technical
substantially equal quarterly installments technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.